Background: Bone mineral density (BMD) as measured by dual-energy X-ray absorptiometry (DXA) is considered the gold standard for the management of osteoporosis. Recently, quantitative ultrasound (QUS), which is easy to use, inexpensive, portable, does not use ionizing radiation, and has also been shown to provide information about bone quality and to predict fracture risk, has gained growing interest in this area. Objectives: The aim of this study was to compare the capability of one-third radius (33% radius) DXA BMD measurements and calcaneal QUS (cQUS) variables for identifying axial osteoporosis as measured by DXA in men. Methods: Axial BMD measurements at the lumbar spine and at the hip (femoral neck and total hip), 1/3 radius BMD of the non-dominant forearm were made using DXA and cQUS variables at both sides as measured twice were obtained in 179 men aged between 24 and 85 years. Osteoporosis was defined based on the WHO criteria in men aged 50 and over, a man having been considered as osteoporotic in the presence of a T-score ≤-2.5 in any of the axial regions measured. For defining axial osteoporosis or BMD below the expected range for age, Z-scores of ≤-2.0 were used in men younger than the age of 50 years. Receiver operating characteristic (ROC) analysis was used to assess the osteoporosis identification capability of measurements.
Background: Only postmenopausal women were in the researcher's focus in the majority of publications on osteoporosis (OP) risk factors (RF) in RA female patients (pts). Meanwhile the data on OP RF in menstruating women presented in the rare available papers are not consistent. Objectives: To identify the major OP RF in RA female pts with normal menstrual cycle. Methods: 51 RA (based on ACR criteria) female pts with normal menstrual cycle aged 20 to 51 years (mean age 41,1±7,9) were examined. The following info was included in each individual pts' files: anthropometric parameters, social and demographic data, case history, clinical examination and lab findings, traditional OP RF, pts' joint status, comorbidities status, pain intensity assessments and VAS evaluation of pts' general health status. Axial bone mineral density (BMD) was measured with DEXA scan using Z-score calculator. Based on the OP status all pts were divided into 2 groups:pts with OP-16 (31,4%), and pts without 6%) . Results: Comparative analyses of the groups showed that: OP pts were younger vs the pts without OP (36,9±10 vs 42,8±6,3 years, p=0,02) . Disease duration was comparable in both groups. Clinical manifestations of inflammation activity (mean DAS 28 score and hsCRP) were statistically significantly more pronounced in the OP group vs the pts without OP (4,91±1,39 vs 4,19±1,06, p=0,049; 27,8 (10,8-43,5) vs 7,4 (1,4-22,7) mg/L, p=0,02, respectively). High DAS 28 (50 vs 20,6%, RR=2,43, 95% CI 1,07-5,53, p=0,03) scores were more often documented in the OP pts. Pronounced feet and hand bone destruction based on the radiographic findings was documented in the majority of pts in both groups, although in the OP pts the joint space narrowing counts (97 (62,5-121) vs 73,5 (53-87), p=0,02) and the total Sharp score (98 (64,5-183) vs 89,0 (63-112), p=0,03) were statistically significantly higher. The OP pts were more often administered oral GCs (81,3 vs 37,1%, RR=2,19, 95% CI 1,34-3,57, p=0,004), as well as GCs -pulse therapy (56, 3 vs 25, 7%, RR=2, 18, 95% CI 1, 45, p=0, 04) , had higher GCs cumulative dose (18,8 (8,1-30,7) vs 6,4 (0,8-14 ,1)g, p<0,01), higher GC daily dose at the time of examination (8,8 (6,3-10) vs 5 (3,8-6,3 )mg/day, p=0,01) and higher average daily dose in the previous year (8,8 (5-10) vs 3,8 (2,5-6,3)mg/day, p=0,01) versus the pts without OP. Analysis of traditional RF (low body weight/BMI, long immobilization periods, smoking, family history of OP and others) showed no difference between the two groups. Discriminant analysis revealed the following major OP RF in the RA female pts before menopause: RA activity (based on the Das 28 score) and GCs dose at the time of examination (given GCs therapy lasts ≥3 months). Meanwhile the patient's body weight and age at the onset of RA were identified as protective factors for BMD. Based on the abovementioned risk and protective factors and the derived coefficients the authors designed a formula allowing to predict of OP in female RA pts before menopause with high accuracy (area under the ROC-curve=0,833). The model accuracy is 85,1%.
Conclusions: RA activity and GCs dose (GCs therapy duration ≥3 months) were identified as the major OP RF in young RA female pts before menopause, thus adequate and timely therapy aimed at obtaining RA control and achieving remission should be considered as key OP prevention strategy. Disclosure of Interest: None declared DOI: 10.1136/annrheumdis-2017-eular.2312
